According to documents, Glaxo began to push sales of Paxil in the early 1990s with an extensive ghostwriting program run by the marketing firm Scientific Therapeutics Information (STI). For instance, STI wrote a proposal to organize GlaxoSmithKline’s Paxil Advisory Board Meeting in 1993 at the Ritz Carlton Hotel in Palm Beach, Florida.
STI chose good ol’ Chuck Nemeroff as their speaker to lay out the meeting’s agenda and objectives. Nemeroff apparently led discussions on how to “evaluate clinical research/promotional programs” and “generate information for use in promotion/education.”
STI’s ghostwriting included editorials, journal articles, and even a textbook that was widely used by primary care physicians to treat psychiatric disorders. Further details here.
[Thanks to Bob Fiddaman for this story].